Sone-190 Today

The molecule belongs to a novel chemotype of spiro‑cyclopropane‑based inhibitors. Key attributes include:

| Property | Value (Pre‑clinical) | |----------|----------------------| | Molecular weight | 378 Da | | LogP | 2.1 (balanced lipophilicity) | | Brain/plasma ratio (rat) | 1.3 | | Oral bioavailability | ~65% | | Half‑life (human) | 12 h (dose‑proportional) |

These characteristics give SONE‑190 good oral exposure and robust CNS penetration, a combination that has eluded many past attempts at targeting TDP‑43. SONE-190

If SONE‑190 continues its upward trajectory, it could redefine therapeutic strategy for TDP‑43 proteinopathies—not only FTD but also ALS, chronic traumatic encephalopathy, and certain forms of Alzheimer's disease where TDP‑43 pathology co‑occurs. The drug’s oral route also opens the door to combination trials, pairing it with antisense therapies that target upstream genetic drivers.

In the broader picture, SONE‑190 exemplifies a new paradigm: leveraging structural biology and AI to discover allosteric sites on intrinsically disordered proteins—a class once considered “undruggable.” Success here could spark a cascade of similar programs across neuro‑degeneration. The molecule belongs to a novel chemotype of

| Company | Candidate | Mechanism | Status (2026) | |---------|-----------|-----------|---------------| | Neurogenix | NGX‑101 | Antisense oligonucleotide (ASO) targeting C9orf72 repeat RNA | Phase 1b (positive safety) | | AstraZeneca | AZ‑D101 | Small‑molecule inhibitor of tau aggregation | Phase 2 | | Biogen | BGN‑202 | Monoclonal antibody against extracellular TDP‑43 | Phase 1 | | Sone Therapeutics | SONE‑190 | Small‑molecule allosteric stabilizer of native TDP‑43 | Phase 1b completed |

While ASOs and antibodies dominate the pipeline, SONE‑190’s oral administration and direct target engagement give it a unique positioning—especially for patients who cannot undergo intrathecal dosing. If SONE‑190 continues its upward trajectory, it could

When a small molecule can cross the blood‑brain barrier, bind a disease‑causing protein with surgical precision, and do so without the safety concerns that have hamstrung previous attempts, the scientific community takes notice. SONE‑190, the lead candidate from Sone Therapeutics, is generating that exact buzz. Early‑phase data suggest it could become the first disease‑modifying therapy for frontotemporal dementia (FTD)—a disorder that currently has no approved treatments and devastates patients and families within a few short years.

But what exactly is SONE‑190? How does it work? And what does its development tell us about the future of neuro‑degenerative drug discovery? This feature pulls together the latest pre‑clinical and clinical data, expert commentary, and the broader context of a field that has long struggled to translate promising biology into medicines.